Industry News

• GTC Biotherapeutics reports fourth quarter and fiscal year end 2009 financial results  The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.
  GTC Biotherapeutics, Inc. March 12, 2010  
• Progenics to advance oral methylnaltrexone into late stage clinical development  Progenics Pharmaceuticals announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010.
  Progenics Pharmaceuticals, Inc. March 12, 2010  
• FDA's Black Box Warning addressed by Genelex's PlavitestT  The FDA added a new black box warning to Plavix, pointing out the importance of individual patient genetics in determining the effectiveness of Plavix treatment. The relabeling is in response to clinical research demonstrating that one-third of patients are in varying degrees of treatment failure.
  Genelex Corporation March 12, 2010  
• Pfizer discontinues a Phase 3 study of figitumumab  Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
  Pfizer Inc. March 11, 2010  
• Two Phase 3 trials of sunitinib did not meet the primary endpoint  Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
  Pfizer Inc. March 11, 2010  
• NxStage(R) secures $15 million revolving line of credit  NxStage Medical announced that it has secured a two-year $15 million revolving line of credit from Silicon Valley Bank. The revolving line of credit is subject to a borrowing base of trade accounts receivable, inventory and field equipment.
  NxStage Medical, Inc. March 11, 2010  
• Abbott seeks FDA approval of a new six-month 45-mg formulation of Lupron(R) Depot  The U.S. Food and Drug Administration(FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron(R) Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.
  Abbott March 11, 2010  
• Cordis unveils next generation CoCr coronary stent  Cordis Corporation announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances.
  Johnson & Johnson March 11, 2010  
• Generex receives positive responses from independent physicians and nurse practitioners  Generex Biotechnology announced that Health Management Resources (HMR) has recently conducted two focus groups in Indianapolis for Generex Oral-lyn(TM).
  Generex Biotechnology Corporation March 11, 2010  
• NMT Medical announces completion of eight-member Scientific Advisory Board  NMT Medical announced the completion of its Scientific Advisory Board (SAB), which is composed of eight industry leading experts from the cardiovascular and neurological medical communities.
  NMT Medical, Inc. March 11, 2010  

   (next 10 articles)